Roberto Negro1, Roberto Attanasio2, Endre V Nagy3, Enrico Papini4, Petros Perros5, Laszlo Hegedüs6. 1. Division of Endocrinology, V. Fazzi Hospital, Lecce, Italy. 2. Endocrine Unit, Galeazzi Orthopedic Institute IRCCS, Milan, Italy. 3. Division of Endocrinology, Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary. 4. Department of Endocrinology and Metabolism, Ospedale Regina Apostolorum, Rome, Italy. 5. Department of Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom. 6. Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark.
Abstract
BACKGROUND: The incidence and prevalence of hypothyroidism are increasing and the threshold for the treatment of hypothyroid as well as individuals without evident thyroid disease with thyroid hormone is declining. OBJECTIVE: To investigate endocrinologists' use of thyroid hormones in hypothyroid and euthyroid patients in Italy, a country where different formulations of levothyroxine (LT4; tablet, liquid solution and soft-gel capsule) are available on the market. METHODS: Members of the Associazione Medici Endocrinologi (Italian Association of Clinical Endocrinologists) were invited to participate in a web-based survey investigating the topic. RESULTS: A total of 797 of 2,028 (39.3%) members completed all the sections of the survey; 98.7% declared that the treatment of choice for hypothyroidism is LT4. A significant minority (37.3%) indicated that LT4 may be considered in infertile euthyroid women seeking pregnancy and harbouring positive thyroperoxidase antibodies (TPOAb) and in goitre increasing in size (18.1%). LT4 + LT3 was considered by 43.2% for LT4-replaced patients and normal TSH, if they reported persistent symptoms. High percentages of respondents chose LT4 in a liquid solution or soft-gel capsules when taken together with other drugs interfering with LT4 absorption (81.8%), in patients with a history of celiac disease, malabsorption, lactose intolerance, intolerance to common excipients (96.6%), or unexplained poor biochemical control of hypothyroidism (74.4%), or in patients not able to adhere to ingesting LT4 fasted and/or separated from food/drink (98.9%). In total, 43.6% of responders would use LT4 in a liquid solution or soft-gel capsules for hypothyroid patients with biochemical euthyroidism on LT4, who had persistent symptoms. CONCLUSIONS: The preferred treatment for hypothyroidism is LT4; LT3 + LT4 combination treatment is mainly considered in patients with persistent symptoms. A significant minority would offer LT4 to euthyroid women with positive TPOAb and infertility and to euthyroid patients with progressive simple goitre. Alternative LT4 formulations like liquid solution or soft-gel capsules are largely reserved for specific conditions (interfering drugs, actual or suspected malabsorption, inability to take LT4 in the fasting state, unexplained poor biochemical control of hypothyroidism).
BACKGROUND: The incidence and prevalence of hypothyroidism are increasing and the threshold for the treatment of hypothyroid as well as individuals without evident thyroid disease with thyroid hormone is declining. OBJECTIVE: To investigate endocrinologists' use of thyroid hormones in hypothyroid and euthyroid patients in Italy, a country where different formulations of levothyroxine (LT4; tablet, liquid solution and soft-gel capsule) are available on the market. METHODS: Members of the Associazione Medici Endocrinologi (Italian Association of Clinical Endocrinologists) were invited to participate in a web-based survey investigating the topic. RESULTS: A total of 797 of 2,028 (39.3%) members completed all the sections of the survey; 98.7% declared that the treatment of choice for hypothyroidism is LT4. A significant minority (37.3%) indicated that LT4 may be considered in infertile euthyroid women seeking pregnancy and harbouring positive thyroperoxidase antibodies (TPOAb) and in goitre increasing in size (18.1%). LT4 + LT3 was considered by 43.2% for LT4-replaced patients and normal TSH, if they reported persistent symptoms. High percentages of respondents chose LT4 in a liquid solution or soft-gel capsules when taken together with other drugs interfering with LT4 absorption (81.8%), in patients with a history of celiac disease, malabsorption, lactose intolerance, intolerance to common excipients (96.6%), or unexplained poor biochemical control of hypothyroidism (74.4%), or in patients not able to adhere to ingesting LT4 fasted and/or separated from food/drink (98.9%). In total, 43.6% of responders would use LT4 in a liquid solution or soft-gel capsules for hypothyroid patients with biochemical euthyroidism on LT4, who had persistent symptoms. CONCLUSIONS: The preferred treatment for hypothyroidism is LT4; LT3 + LT4 combination treatment is mainly considered in patients with persistent symptoms. A significant minority would offer LT4 to euthyroid women with positive TPOAb and infertility and to euthyroid patients with progressive simple goitre. Alternative LT4 formulations like liquid solution or soft-gel capsules are largely reserved for specific conditions (interfering drugs, actual or suspected malabsorption, inability to take LT4 in the fasting state, unexplained poor biochemical control of hypothyroidism).
Authors: Sarah J Peterson; Anne R Cappola; M Regina Castro; Colin M Dayan; Alan P Farwell; James V Hennessey; Peter A Kopp; Douglas S Ross; Mary H Samuels; Anna M Sawka; Peter N Taylor; Jacqueline Jonklaas; Antonio C Bianco Journal: Thyroid Date: 2018-04-05 Impact factor: 6.568
Authors: I Pirola; L Daffini; E Gandossi; D Lombardi; A Formenti; M Castellano; C Cappelli Journal: J Endocrinol Invest Date: 2014-05-01 Impact factor: 4.256
Authors: Torie C Plowden; Enrique F Schisterman; Lindsey A Sjaarda; Shvetha M Zarek; Neil J Perkins; Robert Silver; Noya Galai; Alan H DeCherney; Sunni L Mumford Journal: J Clin Endocrinol Metab Date: 2016-03-29 Impact factor: 5.958
Authors: Nydia Burgos; Freddy J K Toloza; Naykky M Singh Ospina; Juan P Brito; Ramzi G Salloum; Leslie C Hassett; Spyridoula Maraka Journal: Thyroid Date: 2020-12-29 Impact factor: 6.568
Authors: D A Niculescu; R Attanasio; L Hegedüs; E V Nagy; R Negro; E Papini; P Perros; C Poiana Journal: Acta Endocrinol (Buchar) Date: 2020 Oct-Dec Impact factor: 0.877
Authors: Laszlo Hegedüs; Antonio C Bianco; Jacqueline Jonklaas; Simon H Pearce; Anthony P Weetman; Petros Perros Journal: Nat Rev Endocrinol Date: 2022-01-18 Impact factor: 47.564
Authors: K R Riis; J S Frølich; L Hegedüs; R Negro; R Attanasio; E V Nagy; E Papini; P Perros; S J Bonnema Journal: J Endocrinol Invest Date: 2021-03-28 Impact factor: 4.256
Authors: Maria-Cristina Burlacu; Roberto Attanasio; Laszlo Hegedüs; Endre V Nagy; Enrico Papini; Petros Perros; Kiswendsida Sawadogo; Marie Bex; Bernard Corvilain; Chantal Daumerie; Brigitte Decallonne; Damien Gruson; Bruno Lapauw; Rodrigo Moreno Reyes; Patrick Petrossians; Kris Poppe; Annick Van den Bruel; David Unuane Journal: Thyroid Res Date: 2022-03-05
Authors: Juan J Díez; Pedro Iglesias; Agustín García; Ángel Mataix; Francisco A Bernabéu-Andréu Journal: Eur Geriatr Med Date: 2021-08-04 Impact factor: 1.710